瑞银发表研究报告指，恢复覆盖海吉亚医疗(06078.HK) ，维持其“买入”评级，予新目标价20元(原先为73元)。该行认为，市场忽略了海吉亚医疗因市场整合所带来的长期机会，因此该股当前的估值偏低。
瑞银预期，海吉亚医疗的经调整盈利于2023至26年的年均复合增长率为12%。另外，由于集团领先的营运效率、业务策略及在医院扩建及并购方面的良好往绩，因此看好集团的前景。
该行下调集团2024至26年的盈测25%至33%，以反映扩张放缓及近期的报销压力，又下调集团中期现金流增长率预测，由11%降至6.3%，以反映长期医疗照护付款改革预期将导致增长放缓的预测。(sl/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-22 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.